Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

The funding is set to support various activities, including the launch of a confirmatory study of bitopertin for erythropoietic protoporphyria (EPP), Phase II studies for DISC-0974 and DISC-3405 in ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on November 6 and set ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

This financing provides funding options to support anticipated key catalysts, including the expected initiation of a ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...